Welcome Back
Click “Sign in” to agree to Cointime’s Terms of Service and acknowledge that Cointime’s Privacy Policy applies to you.
Join CoinTime
Already have an account?
Click “page.Sign up” to agree to Cointime’s <a class="underline" href="#term-of-service">Terms of Service</a> and acknowledge that Cointime’s a class="underline" href="#privacy-policy">Privacy Policy</a> applies to you.
Sign in with email
Sign up with email
Your email
Check your inbox
Click the link we sent to to sign in.
Click the link we sent to to sign up.
CytoNiche
company
About
CytoNiche is a 3D bionic cell technology company.
- 11 - 50
Details
- Last Funding Type
- Series A
- Industries
- Biotechnology,Health Care
- Founded date
- Jan 1, 2018
- Number Of Employee
- 11 - 50
- Operating Status
- Active
CytoNiche focuses on the development of 3D micro-organization engineering technology. The core technology is derived from the transformation of Tsinghua University's achievements. Based on its original research technology, Huasheng Bio has launched a series of related products and services, including customized, large-scale, automated and intelligent stem cell culture. Amplification process; 3D stem cell micro-tissue regeneration treatment of new drugs and 3D cell high-throughput drug screening products.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
3
¥300M
CytoNiche has raised a total of
¥300M
in funding over 2 rounds. Their latest funding was raised on
Mar 3, 2022 from a Series B round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Mar 3, 2022 | Series B | ¥300M | 1 |
Gaorong Capital
|
— | Detail |
| Sep 3, 2020 | Series A | — | 1 | — | — | Detail |
| Aug 23, 2019 | Series A | — | 1 | — | — | Detail |
Investors
Number of Lead Investors
Number of Investors
1
3
CytoNiche is funded by 3 investors.
Gaorong Capital
and Beijing Shouda Tianji Fund
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
Gaorong Capital
|
Yes | Series B |
|
|
— | Series A |
C&I Capital
|
— | Series A |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
